Is Chemkart India the Best Stock in Its Sector? A Look at the Numbers

Is Chemkart India the best stock in its sector? The stock trades on the BSE at Rs 247 as of 21 October 2026, within its 52-week range of Rs 87.00 to Rs 253.00. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Chemkart India

Chemkart India Ltd, based in Mumbai, is a business to business nutraceutical ingredient distributor and processor, and company information says it was incorporated in 2020. Its main segment is trading, where it sources ingredients such as amino acids, vitamins, herbal extracts and proteins, mostly through imports, and supplies them to clients that make finished supplements. At a market capitalisation of Rs 299 Cr, it is tracked as part of the Nutraceutical Ingredients sector on Univest.

Is Chemkart India the Best Stock in Its Sector?

Chemkart India makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, backed by its return on equity. Chemkart India's 15.23x P/E is below the 63.41x Industry P/E, Neuland Laboratories at 52.07x and Marksans Pharma at 27.32x, while its 15.15% ROE is lower than Neuland Laboratories at 19.42%, though higher than Marksans Pharma at 13.82%, and its debt to equity ratio of 0.04 is below Neuland Laboratories at 0.16 and Marksans Pharma at 0.11.

Metric	Chemkart India
CMP (BSE)	Rs 247.30
52-Week High / Low	Rs 253.00 / Rs 87.00
Market Cap	Rs 299 Cr
P/E (TTM) vs Industry P/E	15.23x vs 63.41x
P/B	2.31
ROE	15.15%
EPS (TTM)	Rs 16.24
Dividend Yield	0.00%
Debt to Equity	0.04

Compare Chemkart India Against Other Nutraceutical Ingredients Sector Stocks

How Chemkart India Compares Against Its Nutraceutical Ingredients Sector Peers

The table below sets Chemkart India against 2 other Nutraceutical Ingredients sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Chemkart India	299	15.23	15.15%	0.04
Neuland Laboratories	25,917	52.07	19.42%	0.16
Marksans Pharma	14,236	27.32	13.82%	0.11
Peer average (2 companies)	-	39.70	16.62%	0.14

Measured against the peer averages, Chemkart India's P/E is 62 percent below the 39.70x average, and its ROE is 1.47 percentage points below the 16.62% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.

What Makes Chemkart India Worth Watching in Nutraceutical Ingredients

• Scale: At Rs 299 Cr, its market capitalisation is smaller than Neuland Laboratories (Rs 25,917 Cr) and Marksans Pharma (Rs 14,236 Cr), which is a useful reminder that the peers differ in size as well as in valuation.
• Sector drivers: Growth in the supplements market and the spread it earns between import cost and selling price drive its profits.
• Key risk: Heavy reliance on imports exposes it to currency moves and supplier changes, and a trading business generally earns lower margins than a manufacturer. The stock has also rallied sharply over the past year.

Chemkart India Valuation: Is It Justified?

At a P/B ratio of 2.31, the market pays about Rs 2.31 for every rupee of book value, and the EPS (TTM) of Rs 16.24 is the earnings base behind the P/E. The stock trades about 2 percent below its 52-week high and about 2.8 times its 52-week low. The company does not currently show a dividend yield, so returns for shareholders depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Chemkart India and other Nutraceutical Ingredients sector stocks.

How to Track Chemkart India Before You Invest

Before deciding whether Chemkart India deserves its label as the best stock in its sector for your own portfolio, compare it directly against Nutraceutical Ingredients sector peers using the steps below.

1. Open the Univest Screener and search for Chemkart India to view live price, valuation ratios, and peer comparisons within the Nutraceutical Ingredients sector.
2. Compare its P/E, P/B, and ROE against other Nutraceutical Ingredients sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Chemkart India gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Nutraceutical Ingredients depends on how much weight you give each of them and on how the business executes from here. Because the stock trades below its sector benchmark, the open question is whether earnings growth will close that gap or whether the discount is deserved. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Chemkart India the best stock in its sector?

Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Chemkart India has a 15.15% ROE and trades at 15.23x P/E against a 63.41x Industry P/E. Against the 2 peers compared in this article, its ROE is below the 16.62% peer average and its P/E is below the 39.70x peer average. Its debt to equity ratio of 0.04 is below the 0.14 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.

What is the current share price of Chemkart India?

Ans. Chemkart India was trading at Rs 247.30 on the BSE as of 21 October 2026, and its 52-week range runs from Rs 87.00 to Rs 253.00. That leaves the share price 2 percent short of the 52-week high and 2.8 times the 52-week low. Its market capitalisation is Rs 299 Cr and its EPS (TTM) is Rs 16.24, which is the earnings figure behind the 15.23x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.

What sector does Chemkart India belong to?

Ans. Chemkart India is classified under the Nutraceutical Ingredients sector on Univest, and that group of listed companies is the reference point for the 63.41x Industry P/E used in this article. The 2 named peers compared here are Neuland Laboratories and Marksans Pharma, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Nutraceutical Ingredients sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.

How does Chemkart India compare to its sector peers on P/E?

Ans. Chemkart India's P/E of 15.23x is below the 39.70x average of the 2 named peers, with Neuland Laboratories at 52.07x and Marksans Pharma at 27.32x. It also sits below the 63.41x Industry P/E, which is the benchmark for the wider Nutraceutical Ingredients sector. A P/E that is below a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 2.31 gives one more view of how the market values its book value.

What is Chemkart India's return on equity?

Ans. Chemkart India reported a return on equity of 15.15%, which is below the 16.62% average of its named peers, with Neuland Laboratories at 19.42% and Marksans Pharma at 13.82%. ROE shows how much profit a company generates on every rupee of shareholders' equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.04 against a peer average of 0.14. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.

Should I invest in Chemkart India based on its sector position?

Ans. Sector position is only one input into an investment decision. Chemkart India has a 15.15% ROE and a 15.23x P/E, which make it worth researching further, and its dividend yield is 0.00%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.